SAN DIEGO--()--KFx Medical Corporation announced that it has been awarded US Patent 8, 267,964 - its fourth knotless double row soft tissue repair patent.
“KFx now has a total of four patents covering knotless double row repair thanks to our inventors, investors, and our intellectual property counsel Knobbe Martens. With their assistance we will continue to expand our intellectual property estate and protect it. Three of our patents are involved in our litigation versus Arthrex, Inc. That case is rapidly proceeding through the court with a trial expected next year,” indicated Tate Scott, president and CEO.
Scott continued, “Quality healthcare depends upon doctors, nurses, and patients having access to the best care, which includes in many cases the latest devices and methods. Inventors and investors have to be fairly rewarded for the risks they take to develop innovative devices and methods such as our double row techniques. Companys’ respect for patents assist in ensuring those fair rewards.”
The new AppianFx line of implants from KFx reattach tissue to and in bone in shoulder, knee, foot and ankle procedures which combined exceed well over 1 million annual surgical procedures in the United States. Product offerings include those that directly place and secure tissue into bone both with and without the use of sutures.
About KFx Medical Corporation
Headquartered in Carlsbad, Calif., KFx Medical Corporation was founded in 2003 to develop products for tissue fixation in a variety of orthopedic surgical procedures performed on the shoulder, knee, foot, and ankle. KFx provides simple systems for orthopedic surgeons focused on sports medicine. The company is privately held — Investors include Alloy Ventures, Charter Life Sciences, Arboretum Ventures, Montreux Equity Partners, and MB Venture Partners.